Literature DB >> 10950238

Effect of thalidomide on gastrointestinal toxic effects of irinotecan.

R Govindarajan, K M Heaton, R Broadwater, A Zeitlin, N P Lang, M Hauer-Jensen.   

Abstract

Irinotecan is the only accepted second-line treatment for colorectal cancer in the USA. Doses are, however, frequently limited by associated late-onset diarrhoea. Thalidomide has antiangiogenic and immunomodulatory properties and is being investigated as an antineoplastic. We did a pilot study of combination therapy with thalidomide and irinotecan for metastatic colorectal cancer. In an interim analysis of nine patients, thalidomide had almost eliminated the dose-limiting gastrointestinal toxic effects of irinotecan, especially diarrhoea and nausea (each p<0.0001), and eight of nine patients were able to complete the chemotherapy course.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10950238     DOI： 10.1016/s0140-6736(00)02586-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  12 in total

Review 1.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

2.  The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.

Authors:  Jacqueline Ramírez; Kehua Wu; Linda Janisch; Theodore Karrison; Larry K House; Federico Innocenti; Ezra E W Cohen; Mark J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  2011-08-23       Impact factor: 3.333

Review 3.  Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage.

Authors:  Joanne M Bowen; Rachel J Gibson; Adrian G Cummins; Dorothy M K Keefe
Journal:  Support Care Cancer       Date:  2006-02-02       Impact factor: 3.603

Review 4.  Thalidomide in cancer treatment: a potential role in the elderly?

Authors:  Shufeng Zhou; Philip Kestell; Malcolm D Tingle; James W Paxton
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

5.  Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.

Authors:  Lisa M McGregor; Clinton F Stewart; Kristine R Crews; Michael Tagen; Amy Wozniak; Jianrong Wu; M Beth McCarville; Fariba Navid; Victor M Santana; Peter J Houghton; Wayne L Furman; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2011-04-20       Impact factor: 3.167

6.  A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.

Authors:  Camilo E Fadul; Linda S Kingman; Louise P Meyer; Bernard F Cole; Clifford J Eskey; C Harker Rhodes; David W Roberts; Herbert B Newton; J Marc Pipas
Journal:  J Neurooncol       Date:  2008-07-26       Impact factor: 4.130

7.  Effective use of panobinostat in combination with other active agents in myeloma in a novel five-drug combination: Case report and interesting observations.

Authors:  Archana M Rajan; Francis K Buadi; Vincent Rajkumar
Journal:  Am J Hematol       Date:  2016-02       Impact factor: 10.047

Review 8.  Thalidomide and its derivatives: emerging from the wilderness.

Authors:  J N Gordon; P M Goggin
Journal:  Postgrad Med J       Date:  2003-03       Impact factor: 2.401

9.  Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.

Authors:  Vinay K Puduvalli; Pierre Giglio; Morris D Groves; Kenneth R Hess; Mark R Gilbert; Srikanth Mahankali; Edward F Jackson; Victor A Levin; Charles A Conrad; Sigmund H Hsu; Howard Colman; John F de Groot; Melesa G Ritterhouse; Sandra E Ictech; W K Alfred Yung
Journal:  Neuro Oncol       Date:  2008-02-26       Impact factor: 12.300

Review 10.  Clinical pharmacokinetics of thalidomide.

Authors:  Steve K Teo; Wayne A Colburn; William G Tracewell; Karin A Kook; David I Stirling; Markian S Jaworsky; Michael A Scheffler; Steve D Thomas; Oscar L Laskin
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 5.577
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.